Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03322293 · ClinicalTrials.gov registry record · Phase 1
Daylight Photodynamic Therapy for Actinic Keratosis
A Phase 1 study of Actinic Keratoses, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03322293: Completed Phase 1 study of Actinic Keratoses, sponsored by University of California, San Francisco.
NCT03322293 is a Phase 1 study of Actinic Keratoses that has completed, run by University of California, San Francisco. The registered enrollment target is 24 participants, below the 96-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03322293, a Phase 1 study of Actinic Keratoses, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, single-blind controlled trial with parallel group design to determine whether daylight photodynamic therapy (PDT) affords a reduction in treatment symptoms of pain, burning, and pruritus as measured by 1) symptom level during the treatment period and 2) pain at the end of treatment exposure.
Primary Outcome
Primary objective is to determine whether daylight PDT changes treatment symptoms of pain, stinging/burning, and itching/pruritus. This was measured using a visual analog scale from 0-10, with higher scores indicating worse treatment symptoms, or more pain/burning/itching. Lower scores indicate less pain, burning/stinging, and itching/pruritus. Positive numbers represent increases in symptoms and negative numbers represent decreases.
Conditions Studied
Interventions
- DRUG Aminolevulinic Acid Topical 20% Topical Solution
- DEVICE BLU-U blue light phototherapy illuminator
Study Locations (1)
California
- UCSF Dermatology - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-07-01 |
| Phase | Phase 1 |
What the finished NCT03322293 record still lists
NCT03322293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 96-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Actinic Keratoses appearing as the primary indexed condition, and to 2 interventions - of which Aminolevulinic Acid Topical 20% Topical Solution is the first listed.
NCT03322293 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03322293 about?
NCT03322293 is a clinical study titled "Daylight Photodynamic Therapy for Actinic Keratosis". This is a randomized, single-blind controlled trial with parallel group design to determine whether daylight photodynamic therapy (PDT) affords a reduction in treatment symptoms of pain, burning, and pruritus as measured by 1) symptom level during the treatment period and 2) pain at the end of treat...
What is the current status of trial NCT03322293?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-12-01. Estimated completion is 2019-07-01.
What conditions does trial NCT03322293 study?
This clinical trial studies the following conditions: Actinic Keratoses.
What interventions are being tested in trial NCT03322293?
The interventions under investigation include: Aminolevulinic Acid Topical 20% Topical Solution (DRUG), BLU-U blue light phototherapy illuminator (DEVICE).
Who is sponsoring clinical trial NCT03322293?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03322293 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratoses
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03322293's enrollment target sits among peer trials
24 10th of 12 higher than 3 of 12 other Actinic Keratoses trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Actinic Keratoses trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage
COMPLETED · Phase 1
-
Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
COMPLETED · Phase 1
-
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
RECRUITING · Phase 4
-
Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
RECRUITING · NA
-
The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population
RECRUITING · NA
-
Photodynamic Therapy Incubation Times for Actinic Keratosis
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI